AstraZeneca PLC $ 55.44 -0.47 (-0.84%)
AZN News and Headlines - AstraZeneca PLC
Shares of Pfizer (PFE) have declined almost 7% since I last looked at the company in depth. Despite this weakness, I believe that the company has strong prospects for growth. The stock continues to offer a dividend yield that is superior to its long-term average while trading with a very low price-earnings multiple.
This article will examine why I think Pfizer remains a strong buy for investors looking for exposure to the health care sector.
Pfizer reported second quarter earnings results on July 28. The company's revenue fell 11% year-over-year to $11.8 billion, but managed to
The last three categories of drugs being studied for Alzheimer's are metabolic approaches, stem cell and gene therapies and alternative medicines. The first four were reviewed previosly, with the most popular approach being aimed at the physical changes (amyloid/tau) in the brains of Alzheimer's patients.
Diabetes is a metabolic disease, so some scientists speculate that Alzheimer's is really the third type of diabetes, according to FierceBiotech. That's because some forms of Alzheimer's seem to be related to insulin resistance, the main problem in type 2 diabetes. Research has shown that people with this form of diabetes have a greater risk
Shares of Bristol-Myers Squibb Co. (BMY) are up roughly 5% since I thought that the stock deserved better than a single-digit price-earnings ratio. I thought previously that Bristol-Myers might have the potential to return better than 50% just with the price-earnings ratio trading within a range closer to that of peers.
Following second-quarter results, that thesis remains in place.
Bristol-Myers reported second-quarter earnings results on Aug. 6. Revenue increased 62% to $10.1 billion, which was $89 million above what Wall Street analysts had expected. Adjusted earnings per share improved 45 cents, or 38%, to $1.63. This
A small Boston-area biotech hopes to usher in a new era in disease treatment by getting regulatory approval for its microbiome drug. Seres Therapeutics Inc. (MCRB) said it expects to meet shortly with the Food and Drug Administration to discuss next steps, and thinks the treatment will approved next year.
Based on the news, investors bid the stock up nearly 500% to more than $26 in less than two weeks. Seres traded near $36 shortly after going public in 2015. Just days ago, the 10-year-old company announced the pricing of an underwritten public offering of 10.5 million shares of its
The "economic advantage" investment process was initially developed by Liontrust to search for businesses with a collection of distinctive characteristics that competitors struggle to match. The British specialist fund management company has seen quite a lot of success so far, as the funds managed based on this thesis have all outperformed their respective benchmarks, including the highly-rated Liontrust UK Growth, Smaller Companies and Micro Cap funds.
The team at Liontrust thinks that all types of economic advantages stem from intangible assets. It regards the following three as being the most difficult advantages for competitors to replicate.
1. Intellectual property
Should the Covid-19 vaccine being developed by Pfizer Inc. (PFE) prove successful, it could give the company a $15 billion shot in the arm.
That’s the potential sales estimated by Bloomberg Intelligence analyst Sam Fazeli for a one-dose regimen of the vaccine, according to a FiercePharma article. Of course, that’s contingent on Pfizer being able to deliver 100 million doses of an effective inoculation.
Pfizer's deal also includes an option for another 500 million doses, RBC Capital Markets analyst Randall Stanicky pointed out, so "investors are increasingly seeing real opportunity here."
Meanwhile, Johnson & Johnson (JNJ), a late entrant to
In a previous article published in GuruFocus, I looked at the top five pharma companies on EvaluatePharma’s list ranked by sales the firms are expected to achieve in 2026. In this piece, we'll go over the next five companies on the list.
Merck & Co. Inc. (MRK)
- Estimated 2026 sales: $51.96 billion
- 2019 sales: $46.2 billion
- 2019-26 CAGR: 3.48%
The cancer drug Keytruda will bear the heaviest responsibility as Merck moves toward projected sales of nearly $52 billion in 2026. By that time, Keytruda is expected to supplant Humira as the best-selling drug in the
Immunomedics (IMMU) has been in the news for a recent change of CEO. The company’s President and CEO Harout Semerjian stepped down and was replaced by Dr. Behzad Aghazadeh.
The company has also been making some fantastic progress on antibody-drug conjugates (ADCs), particularly Trodelvy, which was used to treat its first commerical in the past few weeks. The drug is expected to drive revenues for Immunomedics in 2020.
The company has some promising collaborations with giants such as AstraZeneca (AZN) and Roche (OTCQX:RHHBY). It has also raised funds recently to fund its research for the coming quarters.
Like a race car pushing the pedal to the metal, the stock market sped to its best quarterly stock market gains in decades. The +20% rebound in the 2nd quarter S&P 500 index was the best result achieved since 1998. Moreover, the Dow Jones Industrial Average saw its largest quarterly gain (+18%) since 1987, and the technology-heavy NASDAQ index (+31%) saw the most appreciation since 2001. While a snap-back after a shockingly dismal 1st quarter should come as no surprise to many investors, the pace of this rebound is unlikely to be sustainable at this trajectory, given the challenging economic
ArcherDX has decided to embrace the well-known axiom, “a bird in the hand is worth two in the bush.” Instead of going ahead with its planned $100 million initial public offering, the Colorado-based developer of cancer tests decided to take a $1.4 billion offer from Invitae Corp. (NVTA).
Investors clearly liked the acquisition, pushing shares of Invitae up more than 50% this week to near $29 on June 26. Earlier in the day, the stock price touched more than $30, an all-time high for the 10-year-old San Francisco-based genetic information company.
ArcherDX has more than 325 unique products and is
Even though Roche (RHHBY) was the pharma company that pumped the most money into R&D in 2019 - an astonishing $12.06 billion - AstraZeneca (AZN) recorded the greatest increase in spending at 21%. The company also invested the most as a percentage of sales last year (24.8%).
As we look forward, we see that Covid-19 has thrown a wrench in the plans of pharmaceutical companies. Spending is likely to be down overall in 2020 primarily because a number of clinical trials have been delayed, although some may resume shortly. On the other hand, the pandemic has
AstraZeneca (AZN) was ranked the most the most inventive pharmaceutical company for the second year in a row by IDEA Pharma’s Invention and Innovation Index for 2020. Meanwhile, Roche (RHHBY) jumped seven places from its 2019 ranking to capture the top spot in the list of most innovative pharma firms.
IDEA is an international consulting firm that works with pharma companies to position their products in the early phase to maximize market success and consult on innovation. The firm bases its Innovation Index on the answer to the following question: "If two companies had the same
Bristol-Myers Squibb Co. (BMY) recently reported first-quarter earnings that easily beat analysts’ estimates for revenue and earnings per share. Despite this, shares of the company trade with a forward multiple under 10 times earnings. This development could give investors a golden opportunity to acquire shares of a company that is outperforming expectations while the market significantly undervalues the stock.
Bristol-Myers reported first-quarter earnings results on May 7. The company generated $10.8 billion in revenue, which was an 82% increase from the previous year and $730 million higher than expected. Earnings per share increased 56% to $1.72. This was
Novavax Inc.’s (NVAX) stock is a shadow of its former self, but shares did get a boost when the Gaithersburg, Maryland-based biotech recently received $384 million from a foundation to help the company develop a vaccine against Covid-19. To further aid in the effort, the company filed a prospectus to sell up to $250 million worth of common stock.
The latest cash infusion from the Coalition for Epidemic Preparedness Innovations brings to $388 million the foundation has funneled to Novavax, which is one of several companies working on a Covid-19 immunization.
The award was the largest to date until this
Clovis Oncology Inc. (CLVS) CEO Patrick Mahaffy has made it clear he wants to sell the Boulder, Colorado-based biotech, which focuses on developing cancer drugs. So far, nobody’s come knocking.
That no buyers have stepped up must rankle shareholders, who have seen their investment in the company drop more than 90% in the past five years. Adding to the misery, investors face share dilution, as Clovis is one of eight biotechs going to the secondary markets to raise sorely need cash. he company is planning to sell more than 11 million shares, hoping to raise $85 million.
The fund exited its CVS Health Corp. (CVS) stake. The portfolio was impacted by -1.82%.
The health care services provider has a market cap of $77.59 billion and an enterprise value of $158.84 billion
GuruFocus gives the company a profitability rating of 8 out of 10. The return on equity of 10.85% and return on assets of 3.08% are underperforming 78% of companies in the health care plans industry. Its financial
As Covid-19 floods hospitals in certain affected areas, doctor’s offices around the world are seeing their number of appointments spike as people come in to be tested for the virus.
In addition, some managers are demanding that their employees get “cleared” of the virus by their doctors before returning to work, even if they do not have any symptoms. Given how quickly the virus spreads, some doctors have even noted an unusually high number of clients with mild or no symptoms who want to be tested preemptively.
In response, family care doctors and general practitioners are increasingly moving online in
The following long-term dividend payers thrash the S&P 500 index in terms of a higher dividend yield. The benchmark for the U.S. market yields 1.81% as of Jan. 31.
Therefore, dividend investors may want to consider these companies.
The first company to have a look at is AstraZeneca PLC (AZN).
Shares of the British drug manufacturer closed at $48.7 on Jan. 31 for a market capitalization of $127.8 billion.
Based on this share price, AstraZeneca offers a 2.87% trailing 12-month dividend yield.
In 2019, the company paid the first semi-annual dividend of 95 cents per common share on
It’s that time of the year when investment professionals provide their prognostications for 2020. Some are forecasting a continuation of the long-running bull market, while others think a 15% to 20% correction may be on the horizon. Of course, as the saying goes, “Opinions are like…well, you know—everyone has one.”
A New York Times article said investors should ignore all these predictions. It is true that the prophets are usually right more than they’re wrong. But that’s only because most of the so-called experts say the market will rise the next year, and seven out of 10 times it
Denmark-based Novo Nordisk (OCSE:NOVO B) (NVO) is a global developer of drugs to treat chronic diseases, including diabetes, obesity and hemophilia. The company has sales in 170 countries.
Diabetes and obesity together accounted for 84% of the company’s fiscal 2018 sales. The U.S. is the most significant revenue contributor (49% as of 2018 sales), followed by Europe (19%), Africa, Asia, Middle East and Oceania (11%) and China (10%). Although we are typically cautious about the pipeline risk associated with investing in pharma, we appreciate the strategic focus, dominant market positions and secular growth opportunities at Novo Nordisk.
The company dominates